Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2016 - 2026)

Teva Pharmaceutical Industries' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at $370.0 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 68.18% year-over-year to $370.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 217.3% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.58% from the prior year.
• Net Income towards Common Stockholders was $370.0 million for Q1 2026 at Teva Pharmaceutical Industries, down from $470.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $519.0 million in Q1 2024 and bottomed at -$1.8 billion in Q4 2023.
• A 5-year average of -$273.7 million and a median of -$253.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 1286.59% — and 2024, when it surged 305.14%.
• Teva Pharmaceutical Industries' Net Income towards Common Stockholders stood at -$1.3 billion in 2022, then tumbled by 34.63% to -$1.8 billion in 2023, then jumped by 84.69% to -$275.0 million in 2024, then soared by 270.91% to $470.0 million in 2025, then declined by 21.28% to $370.0 million in 2026.
• Business Quant data shows TEVA's Net Income towards Common Stockholders at $370.0 million in Q1 2026, $470.0 million in Q4 2025, and $432.0 million in Q3 2025.